Dongkook Pharmaceutical Co Stock Current Asset
| 086450 Stock | KRW 16,640 40.00 0.24% |
DongKook Pharmaceutical Co fundamentals help investors to digest information that contributes to DongKook Pharmaceutical's financial success or failures. It also enables traders to predict the movement of DongKook Stock. The fundamental analysis module provides a way to measure DongKook Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DongKook Pharmaceutical stock.
DongKook |
DongKook Pharmaceutical Co Company Current Asset Analysis
DongKook Pharmaceutical's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current DongKook Pharmaceutical Current Asset | 203.59 B |
Most of DongKook Pharmaceutical's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, DongKook Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, DongKook Pharmaceutical Co has a Current Asset of 203.59 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current asset for all Republic of Korea stocks is notably lower than that of the firm.
Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
DongKook Fundamentals
| Return On Equity | 12.72 | |||
| Return On Asset | 0.0608 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 1.08 T | |||
| Shares Outstanding | 8.79 M | |||
| Shares Owned By Insiders | 46.60 % | |||
| Shares Owned By Institutions | 17.00 % | |||
| Price To Earning | 19.52 X | |||
| Price To Sales | 0.24 X | |||
| Revenue | 594.19 B | |||
| Gross Profit | 337.12 B | |||
| EBITDA | 83.48 B | |||
| Net Income | 52.92 B | |||
| Cash And Equivalents | 85.44 B | |||
| Total Debt | 13.69 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 2.61 X | |||
| Book Value Per Share | 23,358 X | |||
| Cash Flow From Operations | 44.65 B | |||
| Target Price | 22667.0 | |||
| Number Of Employees | 1.06 K | |||
| Beta | 1.09 | |||
| Market Capitalization | 145.91 B | |||
| Total Asset | 750.08 B | |||
| Retained Earnings | 172.22 B | |||
| Working Capital | 139.53 B | |||
| Current Asset | 203.59 B | |||
| Current Liabilities | 64.06 B | |||
| Z Score | 6.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 750.08 B |
About DongKook Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DongKook Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DongKook Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DongKook Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with DongKook Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DongKook Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DongKook Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to DongKook Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DongKook Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DongKook Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DongKook Pharmaceutical Co to buy it.
The correlation of DongKook Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DongKook Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DongKook Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DongKook Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in DongKook Stock
DongKook Pharmaceutical financial ratios help investors to determine whether DongKook Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DongKook with respect to the benefits of owning DongKook Pharmaceutical security.